RBC-bound cell-free DNA as a predictor of acute anemia in sickle cell disease
Funded at Emory University · NIH-11292749 · Data updated 2026-11-12
Aims to understand whether DNA released from cells in the blood can forecast sudden drops in hemoglobin in people with sickle cell disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 1, 2026 |
| Project end | February 28, 2031 |
| Funding year | 2026 |
| Award (this year) | $797,648 |
| NIH project number | 1R01HL178546-01A1 |
| Project ID | NIH-11292749 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with sickle cell disease who experience or are at risk for acute drops in hemoglobin and related complications.
✕Less likely to help
Patients without sickle cell disease or those not experiencing anemia crises may not directly benefit.
What this research studies
In sickle cell disease, patients often have a steady level of anemia interrupted by unexpected, dangerous drops in red blood cells. This study looks at cell-free DNA that circulates in the blood and how it relates to these acute anemia events and related complications. It combines measurements of cfDNA and information about red blood cells and immune signals to see if cfDNA can signal an upcoming crisis. The research will involve analyzing patient samples and possibly correlating biomarkers with clinical outcomes to identify potential predictors. If successful, the findings could guide earlier interventions to prevent organ damage during vaso-occlusive episodes.
Why it matters
Potential benefit: If the approach works, patients could benefit from earlier warning signs and targeted treatments to reduce acute anemia events and related complications.
How similar studies have gone: Previous work has linked cell-free DNA with inflammation and complications in SCD, but this specific RBC-bound cfDNA pathway as a predictor is being explored.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Zerra, Patricia Elizabeth — Emory University
- Study coordinator: Zerra, Patricia Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Digital twins of the spleen to help design better therapies for sickle cell disease
A computer-driven replica of the spleen is being developed to speed up creating safer and more effective treatments for people with sickle cell disease.
-
Hydroxyurea to help children with sickle cell anemia in Africa
A pediatric study tests hydroxyurea treatment for young children with sickle cell anemia in several African countries to see if it can reduce illness and improve health.
-
Hydroxyurea for Children with Sickle Cell in Africa
A pilot study tests hydroxyurea in young children with sickle cell disease across several African countries to see if it can reduce illness and hospital visits.
-
Hydroxyurea for Children with Sickle Cell Disease in Africa
A safe and feasible use of hydroxyurea for young children with sickle cell disease in several African countries to reduce illness and improve daily life.
-
Accelerating hydroxyurea use for sickle cell disease in Nigeria
A pragmatic study in Nigeria aims to help doctors use hydroxyurea more consistently for people with sickle cell disease.
-
Immune and nerve signals behind acupuncture relief for sickle cell pain
This NIH grant explores how acupuncture helps reduce pain and opioid use for people with sickle cell disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.